forecast glp-1 prescriptions growth 2025 semaglutide tirzepatide Receptor Agonist Market Report, 2033 Chart: 1 in 8 Americans

GLP-1 Therapeutics and Their Emerging Role in Alcohol and Substance Use Disorders: An Endocrinology Primer

Its dual-action capability places it in a unique position alongside medications such as Zepbound, which are specifically approved for weight management

SGLT2 inhibition reduces glucose reabsorption at the level of the proximal renal tubule, promotes urinary glucose excretion independent of insulin action, and causes a negative caloric balance ( Figure 1 )

Tobb explains, leading to mild calorie loss, modest weight reduction and improved blood sugar control

The FDAs endorsement of these drugs for weight management, irrespective of a diabetes diagnosis, underscores their potential